While examining the relationship of CCN5 mRNA expression levels and clinical outcome of human BC progression using bioinformatically analyzed (SurvExpress program) multiple published global microarray datasets of BC patients with or without receptors (i.e., ER, PR and HER-2)33, we found high expression of CCN5 predicts good prognosis and increase overall patient survival (Fig. 1A and B). Here, ERBB2 is linked to breast cancer.